Home > Publications database > Tumor Versus Capillary Telangiectasia in Recurring Glioblastoma. > print

001     304488
005     20250914022653.0
024 7 _ |a 10.1097/RLU.0000000000006125
|2 doi
024 7 _ |a pmid:40916123
|2 pmid
024 7 _ |a 0363-9762
|2 ISSN
024 7 _ |a 1536-0229
|2 ISSN
024 7 _ |a altmetric:181212012
|2 altmetric
037 _ _ |a DKFZ-2025-01880
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a von Polenz, Isabelle
|0 0009-0002-6288-5134
|b 0
245 _ _ |a Tumor Versus Capillary Telangiectasia in Recurring Glioblastoma.
260 _ _ |a Philadelphia, Pa.
|c 2025
|b Lippincott Williams & Wilkins
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1757570267_26504
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a This image highlights a diagnostic pitfall in a 65-year-old patient with recurrent glioblastoma. 18F-FET-PET revealed 2 hotspots with focally enhanced uptake: local tumor recurrence (TBRmax 2.3) on the left and another lesion in the right anterior cingulate gyrus (TBRmax 1.8), suspicious for a distant tumor manifestation. However, multimodal MRI revealed a benign capillary telangiectasia in the anterior cingulate gyrus. While 18F-FET-PET is highly sensitive for detecting tumor activity, vascular malformations may also exhibit moderate tracer uptake. Therefore, careful interpretation and comparison with multiple MRI sequences are essential.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a FET-PET
|2 Other
650 _ 7 |a diagnostic pitfall
|2 Other
650 _ 7 |a glioblastoma
|2 Other
700 1 _ |a Forbrig, Robert
|b 1
700 1 _ |a Albert, Nathalie L
|0 P:(DE-HGF)0
|b 2
773 _ _ |a 10.1097/RLU.0000000000006125
|0 PERI:(DE-600)2045053-9
|p nn
|t Clinical nuclear medicine
|v nn
|y 2025
|x 0363-9762
909 C O |o oai:inrepo02.dkfz.de:304488
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN NUCL MED : 2022
|d 2024-12-18
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b CLIN NUCL MED : 2022
|d 2024-12-18
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK Koordinierungsstelle München
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21